The impact of AI in the workplace is already profound, but that impact is expected to grow exponentially in the coming years, ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Pfizer has partnered with ‘computation-driven’ pharmaceutical technology company XtalPi to develop a drug development and discovery platform powered by artificial intelligence (AI) ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

1. PostEra. PostEra Announces Expansion to $610M in Their AI Drug Discovery Collaboration with Pfizer. Press Release. Jan. 8, 2025. 2. PostEra. PostEra Provides Update on Progress of the ...

But Pfizer has, in front of it, an opportunity to make a very important announcement, and that is of the head of R&D. At the end of the day, bar farmer, the industry is driven by innovation.

Pfizer named a new Chief Scientific Officer Pfizer on Wednesday promoted its Chief Oncology Officer Chris Boshoff to head all R&D at the company, STAT’s Matthew Herper writes.

As the new head of research, Boshoff will be tasked with revving up a pipeline that some investors have found disappointing. Pfizer achieved an astonishing success developing a COVID-19 vaccine in ...

Pfizer has partnered with ‘computation-driven’ pharmaceutical technology company XtalPi to develop a drug development and discovery platform powered by artificial intelligence (AI) ...